323,078 803,754 923,172 2,489,996
Purchased research
and development 6,556,048 - 6,556,048 -
Selling, general
and administrative 1,767,587 622,518 2,812,002 1,843,534
Total operating
expenses 8,646,713 1,435,717 10,292,778 4,395,264
Loss from operations (8,634,213) (1,412,538) (10,243,158) (4,320,144)
Other income (Expense):
Interest income 21,657 28,604 35,563 109,687
Interest expense (64,131) (4,469) (70,289) (14,439)
Other income, net (42,474) 24,135 (34,726) 95,248
Net loss (8,676,687) (1,388,403) (10,277,884) (4,224,896)
Accretion of dividend on
Series A Convertible
Preferred Stock - (1,479) (483) (4,389)
Net loss applicable
to common
shareholders $(8,676,687) $(1,389,882) $(10,278,367) $(4,229,285)
Net loss per common share,
basic and diluted $(0.70) $(0.49) $(1.05) $(1.60)
Basic and diluted weighted
average common shares
outstanding 12,438,201 2,839,201 9,771,183 2,640,691
'/>"/>SOURCE Echo Therapeutics, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA2.
DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review3.
PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation4.
Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway5.
Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 20076.
Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer7.
ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials8.
Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination9.
Amsterdam Molecular Therapeutics Reports Half Year Results 200710.
Nektar Therapeutics Appoints Lutz Lingnau as New Board Member11.
Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug